Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

Leukemia

Volumn 29, Issue 10, 2015, Pages 2039-2049

  Nijhof, I S ^a,b   Groen, R W J ^a,b   Lokhorst, H M ^a,b   Van Kessel, B ^a   Bloem, A C ^b   Van Velzen, J ^b   De Jong Korlaar, R ^a   Yuan, H ^c   Noort, W A ^a   Klein, S K ^d   Martens, A C M ^a,b   Doshi, P ^e   Sasser, K ^e   Mutis, T ^a,b   Van De Donk, N W C J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c XPand Biotechnology BV   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD38 ANTIGEN; CD59 ANTIGEN; DARATUMUMAB; DECAY ACCELERATING FACTOR; LENALIDOMIDE; RETINOIC ACID; ANTINEOPLASTIC AGENT; CD38 PROTEIN, HUMAN; DNA BINDING PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; RAG2 PROTEIN, MOUSE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; UPREGULATION; ANIMAL; APOPTOSIS; BONE MARROW; CELL PROLIFERATION; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SALVAGE THERAPY; TUMOR CELL CULTURE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD38; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE MARROW; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84943587393     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.123     Document Type: Article

References (39)

1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122-1128
2. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149-157
3. van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2010; 37: 266-283
4. van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2012; 26: 199-213
5. Laubach JP, Tai YT, Richardson PG, Anderson KC. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs 2014; 23: 445-452
6. Dolgin E. Cancer's true breakthroughs. Nat Med 2013; 19: 660-663
7. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001; 25: 1-12
8. Malavasi F. Editorial: CD38 and retinoids: a step toward a cure. J Leukoc Biol 2011; 90: 217-219
9. Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G, et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010; 24: 958-969
10. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011; 118: 3470-3478
11. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-1848
12. Jansen JHM, Boross P, Overdijk MB, van Bueren JJL, Parren PWHI, Leusen JHW. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. ASH Annu Meet Abstr 2012; 120: 2974
13. Groen RW, Noort WA, Raymakers RA, Prins HJ, Aalders L, Hofhuis FM, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012; 120: e9-e16
14. Noort WA, Groen RWJ, Raymakers R, Aalders L, Hofhuis FM, van Kessel B, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of refractory patient-derived multiple myeloma cells, growing in a novel humanized mouse MM model. ASH Annu Meet Abstr 2012; 120: 940
15. Lokhorst H, Laubach JP, Nahi H, Plesner T, Gimsing P, Hansson M, et al. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). J Clin Oncol 2014; 32: 8513
16. van der Veer M, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96: 284-290
17. Nijhof IS, van Noort W, Lammerts van Bueren J, van Kessel B, Bakker J, Parren P, et al. CD38-Targeted immunochemotherapy of multiple myeloma: preclinical evidence for its combinatorial use in lenalidomide and bortezomib refractory/intolerant MM patients. Blood 2013; 122: 277
18. Nijhof IS, Groen RW, Noort WA, van KB, de Jong-Korlaar RA, Bakker JM, et al. Preclinical evidence for the therapeutic potential of CD38-Targeted immunochemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2014
19. Plesner T, Arkenau T, Lokhorst H, Gimsing P, Krejcik J, Lemech C, et al. Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. Blood 2013; 122: 1986
20. Plesner T, Arkenau T, Lokhorst HM, Gimsing P, Krejcik J. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Blood 2014; 124: 84
21. van der Veer M, de Weers M, van KB, Bakker JM, Wittebol S, Parren PW, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 2011; 1: e41
22. Nijhof IS, de Weers M, Andre P, van Kessel B, Lokhorst HM, Parren PWHI, et al. Synergistic action of the human inhibitory KIR antibody IPH2102, and the human CD38 antibody daratumumab to enhance the lysis of primary multiple myeloma (MM) cells in the bone marrow mononuclear cells (MNCs) from myeloma patients. ASH Annu Meet Abstr 2011; 118: 1865
23. de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, et al. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance. Clin Cancer Res 2013; 19: 5591-5601
24. Drach J, McQueen T, Engel H, Andreeff M, Robertson KA, Collins SJ, et al. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-Alpha. Cancer Res 1994; 54: 1746-1752
25. Meyer S, Leusen JH, Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs 2014; 6: 1133-1144
26. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12: 4027-4035
27. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-3389
28. Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, et al. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximabresistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 2011; 17: 6702-6711
29. Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S, et al. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin Cancer Res 2009; 15: 3624-3632
30. Suzuki Y, Yoshida T, Wang G, Togano T, Miyamoto S, Miyazaki K, et al. Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL. Ann Hematol 2012; 91: 997-1005
31. Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009; 113: 3773-3780
32. Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012; 7: e39416
33. Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, et al. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013; 141: 43-53
34. Lipton A, Kostler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, et al. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 2010; 116: 5168-5178
35. Benson Jr. DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286-2294
36. Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 2002; 43: 1773-1808
37. Uruno A, Noguchi N, Matsuda K, Nata K, Yoshikawa T, Chikamatsu Y, et al. All-Trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta. J Leukoc Biol 2011; 90: 235-247
38. Kishimoto H, Hoshino S, Ohori M, Kontani K, Nishina H, Suzawa M, et al. Molecular mechanism of human CD38 gene expression by retinoic acid. Identification of retinoic acid response element in the first intron. J Biol Chem 1998; 273: 15429-15434
39. Lewandowski D, Linassier C, Iochmann S, Degenne M, Domenech J, Colombat P, et al. Phosphatidylinositol 3-kinases are involved in the all-Trans retinoic acidinduced upregulation of CD38 antigen on human haematopoietic cells. Br J Haematol 2002; 118: 535-544